Katalog der Deutschen Nationalbibliothek

Neuigkeiten Servicezeiten in Frankfurt am Main ab 1. Dezember 2025: Montag bis Freitag 9–18 Uhr und Samstag 10–16 Uhr
Service hours in Frankfurt am Main from 1 December 2025: Monday to Friday 9:00-18:00 and Saturday 10:00-16:00
 
Neuigkeiten

Leichte Bedienung, intuitive Suche: Die Betaversion unseres neuen Katalogs ist online! → Zur Betaversion des neuen DNB-Katalogs

 
Neuigkeiten 24. Dezember 2025 bis 1. Januar 2026: Die Deutsche Nationalbibliothek bleibt an beiden Standorten geschlossen. Bestellte Medien werden am 2. Januar 2026 bereitgestellt. // 24 December 2025 to 1 January 2026: The German National Library will be closed at both locations. Ordered media will be made available on 2 January 2026.
 
 
 


Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

121 - 130 von 138
<< < > >>


Artikel 121 Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience
Enthalten in Internal and emergency medicine Bd. 18, 24.2.2023, Nr. 3, date:4.2023: 791-799
Online Ressource
Artikel 122 Kein Nachteil durch Wechsel zwischen Biosimilar und Originator
Enthalten in Hautnah / Dermatologie Bd. 34, 12.5.2018, Nr. 3, date:5.2018: 28-29
Online Ressource
Artikel 123 Label discrepancies between originator and generic drugs impact safety
Enthalten in Reactions weekly Bd. 1802, 2.5.2020, Nr. 1, date:5.2020: 8
Online Ressource
Artikel 124 Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
Enthalten in Advances in therapy Bd. 35, 6.8.2018, Nr. 9, date:9.2018: 1295-1332
Online Ressource
Artikel 125 Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
Enthalten in BioDrugs Bd. 32, 29.9.2018, Nr. 5, date:10.2018: 397-404
Online Ressource
Artikel 126 Originator-to-biosimilar non-medical switch may not yield such great cost savings
Enthalten in PharmacoEconomics & outcomes news Bd. 892, 27.11.2021, Nr. 1, date:11.2021: 17
Online Ressource
Artikel 127 Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries
Enthalten in Rheumatology and therapy Bd. 10, 12.1.2023, Nr. 2, date:4.2023: 433-445
Online Ressource
Artikel 128 Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists
Enthalten in BioDrugs Bd. 31, 19.9.2017, Nr. 5, date:10.2017: 447-459
Online Ressource
Artikel 129 Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
Enthalten in BioDrugs Bd. 27, 7.5.2013, Nr. 5, date:10.2013: 495-507
Online Ressource
Artikel 130 Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia
Enthalten in BMC Rheumatology Bd. 6, 27.1.2022, Nr. 1, date:12.2022: 1-9
Online Ressource


121 - 130 von 138
<< < > >>


E-Mail-IconAdministration